Coronary heart disease other diagnostic studies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
/* ACC/AHA/ESC 2006 Guidelines (DO NOT EDIT) {{cite journal| author=Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al.| title=ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Preventio... |
||
| Line 11: | Line 11: | ||
|- | |- | ||
| bgcolor="LightGreen"| <nowiki>"</nowiki>'''1''' EP testing is recommended for diagnostic evaluation of patients with remote MI with symptoms suggestive of ventricular tachyarrhythmias, including palpitations, presyncope, and syncope. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | | bgcolor="LightGreen"| <nowiki>"</nowiki>'''1.''' EP testing is recommended for diagnostic evaluation of patients with remote MI with symptoms suggestive of ventricular tachyarrhythmias, including palpitations, presyncope, and syncope. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LightGreen"| <nowiki>"</nowiki>'''2''' EP testing is recommended in patients with CHD to guide and assess the efficacy of VT ablation. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | | bgcolor="LightGreen"| <nowiki>"</nowiki>'''2.''' EP testing is recommended in patients with CHD to guide and assess the efficacy of VT ablation. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LightGreen"| <nowiki>"</nowiki>'''3''' EP testing is useful in patients with CHD for the diagnostic evaluation of wide-QRS-complex tachycardias of unclear mechanism. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | | bgcolor="LightGreen"| <nowiki>"</nowiki>'''3.''' EP testing is useful in patients with CHD for the diagnostic evaluation of wide-QRS-complex tachycardias of unclear mechanism. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | ||
|} | |} | ||
| Line 26: | Line 26: | ||
|- | |- | ||
|bgcolor="LemonChiffon"| <nowiki>"</nowiki>'''1''' EP testing is reasonable for risk stratification in patients with remote MI, NSVT, and LVEF equal to or less than 40%. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |bgcolor="LemonChiffon"| <nowiki>"</nowiki>'''1.''' EP testing is reasonable for risk stratification in patients with remote MI, NSVT, and LVEF equal to or less than 40%. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
|} | |} | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
Revision as of 15:55, 26 November 2012
|
Coronary heart disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Coronary heart disease other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Coronary heart disease other diagnostic studies |
|
Risk calculators and risk factors for Coronary heart disease other diagnostic studies |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
ACC/AHA/ESC 2006 Guidelines (DO NOT EDIT) [1]
Electrophysiological Testing in Patients With Coronary Heart Disease Recommendations
| Class I |
| "1. EP testing is recommended for diagnostic evaluation of patients with remote MI with symptoms suggestive of ventricular tachyarrhythmias, including palpitations, presyncope, and syncope. (Level of Evidence: B) " |
| "2. EP testing is recommended in patients with CHD to guide and assess the efficacy of VT ablation. (Level of Evidence: B) " |
| "3. EP testing is useful in patients with CHD for the diagnostic evaluation of wide-QRS-complex tachycardias of unclear mechanism. (Level of Evidence: C) " |
| Class IIa |
| "1. EP testing is reasonable for risk stratification in patients with remote MI, NSVT, and LVEF equal to or less than 40%. (Level of Evidence: B)" |
References
- ↑ Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M; et al. (2006). "ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society". Circulation. 114 (10): e385–484. doi:10.1161/CIRCULATIONAHA.106.178233. PMID 16935995.